1. The BNT162b2 mRNA Vaccine Against SARS-CoV-2 Reprograms Both Adaptive and Innate Immune Responses
- Author
-
Ronald P. van Rij, Heidi Lemmers, Yang Li, Gijs J. Overheul, S. Andrei Sarlea, F. Konstantin Föhse, Gizem Kilic, Jorge Domínguez-Andrés, Josephine van de Maat, Jacobien Hoogerwerf, Bart L. Haagmans, Corine H. Geurts van Kessel, Maartje Reijnders, Reinout van Crevel, Büsranur Geckin, Elles Simonetti, Leo A. B. Joosten, Marien I. de Jonge, Ozlem Bulut, Frank L. van de Veerdonk, Mihai G. Netea, Helga Dijkstra, and Jaap ten Oever
- Subjects
Vaccination ,Cellular immunity ,Cytokine ,Immune system ,Innate immune system ,medicine.medical_treatment ,Immunology ,medicine ,TLR4 ,TLR7 ,biochemical phenomena, metabolism, and nutrition ,Biology ,Proinflammatory cytokine - Abstract
SummaryThe mRNA-based BNT162b2 vaccine from Pfizer/BioNTech was the first registered COVID-19 vaccine and has been shown to be up to 95% effective in preventing SARS-CoV-2 infections. Little is known about the broad effects of the new class of mRNA vaccines, especially whether they have combined effects on innate and adaptive immune responses. Here we confirmed that BNT162b2 vaccination of healthy individuals induced effective humoral and cellular immunity against several SARS-CoV-2 variants. Interestingly, however, the BNT162b2 vaccine also modulated the production of inflammatory cytokines by innate immune cells upon stimulation with both specific (SARS-CoV-2) and non-specific (viral, fungal and bacterial) stimuli. The response of innate immune cells to TLR4 and TLR7/8 ligands was lower after BNT162b2 vaccination, while fungi-induced cytokine responses were stronger. In conclusion, the mRNA BNT162b2 vaccine induces complex functional reprogramming of innate immune responses, which should be considered in the development and use of this new class of vaccines.
- Published
- 2021
- Full Text
- View/download PDF